Recent Progress in Regenerative Therapy Using Blood-Derived Biomaterials

Dear Colleagues,

In this Special Issue, we would like to provide a platform to exchange your unique basic findings and concepts of platelet-rich plasma (PRP) therapy and together overcome the current difficulties faced in PRP therapy.

PRP and its derivatives of blood-derived biomaterials seem to have lost their established position as the most attractive materials for regenerative medicine. However, this analysis is based only on the number of scientific publications. Considering that PRP has been constantly or increasingly used in the fields of orthopedic surgery, plastic surgery, and esthetic surgery, PRP therapy is still accepted as the first-line treatment among many clinicians and patients. PRP therapy is considered the only option for regenerative therapy, especially in countries and regions where competing therapeutic options are expensive.

Despite these conditions, why does it look like the sun is setting on PRP therapy? Ten years ago, we proposed the necessity for standardization of PRP preparation and therapy. Several years later, we indicated the flaw of the clinical studies previously conducted and mentioned our prediction of an unavoidable decline of PRP therapy when many papers regarding clinical studies, systematic reviews, and meta-analyses have been published. However, our campaign was not widely accepted and could not change the minds of the clinicians and researchers.

The popularity of therapeutic modalities is severely influenced by many factors such as potency, cost, availability, and individual differences. However, even though a certain therapy has lost its popularity, it does not necessarily imply that it also loses its potential power. PRP therapy is currently at a deadlock. To break these current conditions, we need to swiftly update our knowledge based on scientific evidence from the molecular and cellular levels.

We handle submissions from all fields of regenerative medicine; however, submissions related to sports medicine, orthopedic surgery, and transfusion are particularly welcome.

Dr. Tomoyuki Kawase
Dr. Takashi Ushiki
Dr. Tomoharu Mochizuki
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• blood-derived biomaterial
• platelet-rich plasma
• autologous protein solution
• mechanism
• platelet
• coagulation